nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—CYP2D6—Fingolimod—multiple sclerosis	0.0922	0.125	CbGbCtD
Levomilnacipran—ABCB1—Methylprednisolone—multiple sclerosis	0.0631	0.0855	CbGbCtD
Levomilnacipran—CYP3A4—Fingolimod—multiple sclerosis	0.0586	0.0795	CbGbCtD
Levomilnacipran—CYP2C19—Prednisone—multiple sclerosis	0.0474	0.0642	CbGbCtD
Levomilnacipran—ABCB1—Mitoxantrone—multiple sclerosis	0.046	0.0624	CbGbCtD
Levomilnacipran—ABCB1—Betamethasone—multiple sclerosis	0.041	0.0556	CbGbCtD
Levomilnacipran—ABCB1—Prednisolone—multiple sclerosis	0.0405	0.0549	CbGbCtD
Levomilnacipran—ABCB1—Prednisone—multiple sclerosis	0.0382	0.0518	CbGbCtD
Levomilnacipran—CYP3A4—Methylprednisolone—multiple sclerosis	0.0378	0.0513	CbGbCtD
Levomilnacipran—CYP2C8—Dexamethasone—multiple sclerosis	0.0352	0.0478	CbGbCtD
Levomilnacipran—CYP2C19—Dexamethasone—multiple sclerosis	0.0296	0.0401	CbGbCtD
Levomilnacipran—CYP3A4—Triamcinolone—multiple sclerosis	0.0286	0.0388	CbGbCtD
Levomilnacipran—CYP3A4—Mitoxantrone—multiple sclerosis	0.0276	0.0374	CbGbCtD
Levomilnacipran—CYP3A4—Betamethasone—multiple sclerosis	0.0246	0.0333	CbGbCtD
Levomilnacipran—CYP3A4—Prednisolone—multiple sclerosis	0.0242	0.0329	CbGbCtD
Levomilnacipran—ABCB1—Dexamethasone—multiple sclerosis	0.0239	0.0324	CbGbCtD
Levomilnacipran—CYP3A4—Prednisone—multiple sclerosis	0.0229	0.0311	CbGbCtD
Levomilnacipran—CYP2D6—Dexamethasone—multiple sclerosis	0.0225	0.0305	CbGbCtD
Levomilnacipran—ABCB1—Methotrexate—multiple sclerosis	0.0192	0.026	CbGbCtD
Levomilnacipran—CYP3A4—Dexamethasone—multiple sclerosis	0.0143	0.0194	CbGbCtD
Levomilnacipran—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00194	0.0426	CbGpPWpGaD
Levomilnacipran—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00194	0.0426	CbGpPWpGaD
Levomilnacipran—CYP2J2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00192	0.042	CbGpPWpGaD
Levomilnacipran—CYP2J2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00192	0.042	CbGpPWpGaD
Levomilnacipran—CYP2J2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00158	0.0345	CbGpPWpGaD
Levomilnacipran—CYP2J2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00158	0.0345	CbGpPWpGaD
Levomilnacipran—SLC6A2—nerve—multiple sclerosis	0.00125	0.105	CbGeAlD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.00106	0.0233	CbGpPWpGaD
Levomilnacipran—CYP2J2—Biological oxidations—CYP27B1—multiple sclerosis	0.000837	0.0183	CbGpPWpGaD
Levomilnacipran—CYP2J2—Biological oxidations—CYP24A1—multiple sclerosis	0.000837	0.0183	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000825	0.0181	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000825	0.0181	CbGpPWpGaD
Levomilnacipran—CYP2J2—medulla oblongata—multiple sclerosis	0.000791	0.0661	CbGeAlD
Levomilnacipran—SLC6A4—Serotonin Transporter Activity—IL1B—multiple sclerosis	0.000724	0.0159	CbGpPWpGaD
Levomilnacipran—CYP2J2—midbrain—multiple sclerosis	0.000723	0.0604	CbGeAlD
Levomilnacipran—CYP2J2—spinal cord—multiple sclerosis	0.000705	0.0589	CbGeAlD
Levomilnacipran—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000666	0.0146	CbGpPWpGaD
Levomilnacipran—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000666	0.0146	CbGpPWpGaD
Levomilnacipran—SLC6A4—brainstem—multiple sclerosis	0.000612	0.0511	CbGeAlD
Levomilnacipran—CYP2J2—nervous system—multiple sclerosis	0.000594	0.0497	CbGeAlD
Levomilnacipran—CYP2J2—central nervous system—multiple sclerosis	0.000572	0.0478	CbGeAlD
Levomilnacipran—CYP2J2—cerebellum—multiple sclerosis	0.000559	0.0467	CbGeAlD
Levomilnacipran—SLC6A2—brainstem—multiple sclerosis	0.000538	0.045	CbGeAlD
Levomilnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—multiple sclerosis	0.000533	0.0117	CbGpPWpGaD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000485	0.0106	CbGpPWpGaD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000485	0.0106	CbGpPWpGaD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000479	0.0105	CbGpPWpGaD
Levomilnacipran—CYP2C8—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000479	0.0105	CbGpPWpGaD
Levomilnacipran—CYP2J2—brain—multiple sclerosis	0.000454	0.038	CbGeAlD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.000442	0.00968	CbGpPWpGaD
Levomilnacipran—CYP2J2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000437	0.00958	CbGpPWpGaD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000433	0.00949	CbGpPWpGaD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000433	0.00949	CbGpPWpGaD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000427	0.00936	CbGpPWpGaD
Levomilnacipran—CYP2C19—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000427	0.00936	CbGpPWpGaD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00041	0.00899	CbGpPWpGaD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00041	0.00899	CbGpPWpGaD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000398	0.00873	CbGpPWpGaD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000398	0.00873	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000393	0.00862	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000393	0.00862	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000393	0.00861	CbGpPWpGaD
Levomilnacipran—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000393	0.00861	CbGpPWpGaD
Levomilnacipran—SLC6A4—midbrain—multiple sclerosis	0.00039	0.0326	CbGeAlD
Levomilnacipran—SLC6A4—spinal cord—multiple sclerosis	0.00038	0.0318	CbGeAlD
Levomilnacipran—ABCB1—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000379	0.00831	CbGpPWpGaD
Levomilnacipran—SLC6A2—medulla oblongata—multiple sclerosis	0.000375	0.0314	CbGeAlD
Levomilnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—multiple sclerosis	0.000372	0.00816	CbGpPWpGaD
Levomilnacipran—Convulsion—Prednisolone—multiple sclerosis	0.000367	0.00179	CcSEcCtD
Levomilnacipran—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000367	0.00179	CcSEcCtD
Levomilnacipran—Hypertension—Prednisolone—multiple sclerosis	0.000366	0.00178	CcSEcCtD
Levomilnacipran—Fatigue—Mitoxantrone—multiple sclerosis	0.000364	0.00177	CcSEcCtD
Levomilnacipran—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000363	0.00796	CbGpPWpGaD
Levomilnacipran—Constipation—Mitoxantrone—multiple sclerosis	0.000361	0.00176	CcSEcCtD
Levomilnacipran—Diarrhoea—Azathioprine—multiple sclerosis	0.000357	0.00174	CcSEcCtD
Levomilnacipran—CYP2J2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000354	0.00777	CbGpPWpGaD
Levomilnacipran—Hallucination—Prednisone—multiple sclerosis	0.000352	0.00172	CcSEcCtD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000351	0.00769	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000351	0.00769	CbGpPWpGaD
Levomilnacipran—Syncope—Triamcinolone—multiple sclerosis	0.00035	0.0017	CcSEcCtD
Levomilnacipran—Syncope—Methylprednisolone—multiple sclerosis	0.000349	0.0017	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Prednisone—multiple sclerosis	0.000348	0.0017	CcSEcCtD
Levomilnacipran—Dysuria—Methotrexate—multiple sclerosis	0.000345	0.00168	CcSEcCtD
Levomilnacipran—Neutropenia—Methotrexate—multiple sclerosis	0.000345	0.00168	CcSEcCtD
Levomilnacipran—Dizziness—Azathioprine—multiple sclerosis	0.000345	0.00168	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000345	0.00168	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000343	0.00167	CcSEcCtD
Levomilnacipran—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000343	0.00167	CcSEcCtD
Levomilnacipran—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000342	0.00167	CcSEcCtD
Levomilnacipran—Shock—Prednisolone—multiple sclerosis	0.00034	0.00166	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Methotrexate—multiple sclerosis	0.00034	0.00166	CcSEcCtD
Levomilnacipran—Convulsion—Triamcinolone—multiple sclerosis	0.000338	0.00165	CcSEcCtD
Levomilnacipran—Tachycardia—Prednisolone—multiple sclerosis	0.000338	0.00165	CcSEcCtD
Levomilnacipran—Convulsion—Methylprednisolone—multiple sclerosis	0.000337	0.00164	CcSEcCtD
Levomilnacipran—Hypertension—Triamcinolone—multiple sclerosis	0.000337	0.00164	CcSEcCtD
Levomilnacipran—Hypertension—Methylprednisolone—multiple sclerosis	0.000336	0.00164	CcSEcCtD
Levomilnacipran—Urticaria—Mitoxantrone—multiple sclerosis	0.000335	0.00163	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.000335	0.00734	CbGpPWpGaD
Levomilnacipran—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000334	0.00163	CcSEcCtD
Levomilnacipran—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000333	0.00163	CcSEcCtD
Levomilnacipran—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000333	0.00163	CcSEcCtD
Levomilnacipran—Vomiting—Azathioprine—multiple sclerosis	0.000332	0.00162	CcSEcCtD
Levomilnacipran—Eye disorder—Prednisone—multiple sclerosis	0.000331	0.00161	CcSEcCtD
Levomilnacipran—Anxiety—Methylprednisolone—multiple sclerosis	0.00033	0.00161	CcSEcCtD
Levomilnacipran—Rash—Azathioprine—multiple sclerosis	0.000329	0.0016	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000329	0.0016	CcSEcCtD
Levomilnacipran—Dermatitis—Azathioprine—multiple sclerosis	0.000329	0.0016	CcSEcCtD
Levomilnacipran—Flushing—Prednisone—multiple sclerosis	0.000328	0.0016	CcSEcCtD
Levomilnacipran—Headache—Azathioprine—multiple sclerosis	0.000327	0.00159	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000327	0.00159	CcSEcCtD
Levomilnacipran—Dry mouth—Triamcinolone—multiple sclerosis	0.000325	0.00158	CcSEcCtD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000323	0.00708	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000323	0.00708	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000321	0.00704	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000321	0.00704	CbGpPWpGaD
Levomilnacipran—Angiopathy—Prednisone—multiple sclerosis	0.000321	0.00157	CcSEcCtD
Levomilnacipran—SLC6A4—nervous system—multiple sclerosis	0.00032	0.0268	CbGeAlD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000319	0.007	CbGpPWpGaD
Levomilnacipran—Syncope—Dexamethasone—multiple sclerosis	0.000317	0.00155	CcSEcCtD
Levomilnacipran—Syncope—Betamethasone—multiple sclerosis	0.000317	0.00155	CcSEcCtD
Levomilnacipran—Infection—Triamcinolone—multiple sclerosis	0.000316	0.00154	CcSEcCtD
Levomilnacipran—Infection—Methylprednisolone—multiple sclerosis	0.000315	0.00154	CcSEcCtD
Levomilnacipran—Haematuria—Methotrexate—multiple sclerosis	0.000314	0.00153	CcSEcCtD
Levomilnacipran—Shock—Triamcinolone—multiple sclerosis	0.000313	0.00153	CcSEcCtD
Levomilnacipran—Insomnia—Prednisolone—multiple sclerosis	0.000313	0.00153	CcSEcCtD
Levomilnacipran—Shock—Methylprednisolone—multiple sclerosis	0.000312	0.00152	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000312	0.00152	CcSEcCtD
Levomilnacipran—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000311	0.00152	CcSEcCtD
Levomilnacipran—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000311	0.00152	CcSEcCtD
Levomilnacipran—Loss of consciousness—Betamethasone—multiple sclerosis	0.000311	0.00152	CcSEcCtD
Levomilnacipran—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000311	0.00152	CcSEcCtD
Levomilnacipran—Paraesthesia—Prednisolone—multiple sclerosis	0.000311	0.00151	CcSEcCtD
Levomilnacipran—Tachycardia—Triamcinolone—multiple sclerosis	0.00031	0.00151	CcSEcCtD
Levomilnacipran—Mental disorder—Prednisone—multiple sclerosis	0.00031	0.00151	CcSEcCtD
Levomilnacipran—Nausea—Azathioprine—multiple sclerosis	0.00031	0.00151	CcSEcCtD
Levomilnacipran—Tachycardia—Methylprednisolone—multiple sclerosis	0.00031	0.00151	CcSEcCtD
Levomilnacipran—SLC6A4—central nervous system—multiple sclerosis	0.000308	0.0258	CbGeAlD
Levomilnacipran—Skin disorder—Methylprednisolone—multiple sclerosis	0.000308	0.0015	CcSEcCtD
Levomilnacipran—SLC6A4—Monoamine Transport—IL1B—multiple sclerosis	0.000308	0.00675	CbGpPWpGaD
Levomilnacipran—Malnutrition—Prednisone—multiple sclerosis	0.000308	0.0015	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000308	0.0015	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000307	0.0015	CcSEcCtD
Levomilnacipran—Convulsion—Dexamethasone—multiple sclerosis	0.000306	0.00149	CcSEcCtD
Levomilnacipran—Convulsion—Betamethasone—multiple sclerosis	0.000306	0.00149	CcSEcCtD
Levomilnacipran—Hypertension—Dexamethasone—multiple sclerosis	0.000305	0.00149	CcSEcCtD
Levomilnacipran—Hypertension—Betamethasone—multiple sclerosis	0.000305	0.00149	CcSEcCtD
Levomilnacipran—Asthenia—Mitoxantrone—multiple sclerosis	0.000303	0.00148	CcSEcCtD
Levomilnacipran—Anxiety—Betamethasone—multiple sclerosis	0.0003	0.00146	CcSEcCtD
Levomilnacipran—Anxiety—Dexamethasone—multiple sclerosis	0.0003	0.00146	CcSEcCtD
Levomilnacipran—Hypotension—Methylprednisolone—multiple sclerosis	0.000297	0.00145	CcSEcCtD
Levomilnacipran—Hepatitis—Methotrexate—multiple sclerosis	0.000296	0.00144	CcSEcCtD
Levomilnacipran—CYP2D6—brainstem—multiple sclerosis	0.000295	0.0246	CbGeAlD
Levomilnacipran—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000292	0.00142	CcSEcCtD
Levomilnacipran—Vision blurred—Prednisone—multiple sclerosis	0.00029	0.00142	CcSEcCtD
Levomilnacipran—Urethral disorder—Methotrexate—multiple sclerosis	0.00029	0.00141	CcSEcCtD
Levomilnacipran—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000289	0.00141	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—C4A—multiple sclerosis	0.000288	0.00632	CbGpPWpGaD
Levomilnacipran—Insomnia—Triamcinolone—multiple sclerosis	0.000288	0.0014	CcSEcCtD
Levomilnacipran—Insomnia—Methylprednisolone—multiple sclerosis	0.000287	0.0014	CcSEcCtD
Levomilnacipran—Infection—Betamethasone—multiple sclerosis	0.000287	0.0014	CcSEcCtD
Levomilnacipran—Infection—Dexamethasone—multiple sclerosis	0.000287	0.0014	CcSEcCtD
Levomilnacipran—Paraesthesia—Triamcinolone—multiple sclerosis	0.000286	0.00139	CcSEcCtD
Levomilnacipran—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000285	0.00139	CcSEcCtD
Levomilnacipran—Shock—Dexamethasone—multiple sclerosis	0.000284	0.00139	CcSEcCtD
Levomilnacipran—Shock—Betamethasone—multiple sclerosis	0.000284	0.00139	CcSEcCtD
Levomilnacipran—Dyspnoea—Triamcinolone—multiple sclerosis	0.000284	0.00138	CcSEcCtD
Levomilnacipran—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000283	0.00138	CcSEcCtD
Levomilnacipran—Nervous system disorder—Betamethasone—multiple sclerosis	0.000283	0.00138	CcSEcCtD
Levomilnacipran—Agitation—Prednisone—multiple sclerosis	0.000283	0.00138	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000283	0.00138	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000283	0.00138	CcSEcCtD
Levomilnacipran—SLC6A2—nervous system—multiple sclerosis	0.000282	0.0236	CbGeAlD
Levomilnacipran—Tachycardia—Dexamethasone—multiple sclerosis	0.000282	0.00137	CcSEcCtD
Levomilnacipran—Tachycardia—Betamethasone—multiple sclerosis	0.000282	0.00137	CcSEcCtD
Levomilnacipran—Dyspepsia—Triamcinolone—multiple sclerosis	0.00028	0.00137	CcSEcCtD
Levomilnacipran—Erythema multiforme—Methotrexate—multiple sclerosis	0.00028	0.00136	CcSEcCtD
Levomilnacipran—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000279	0.00136	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000279	0.00136	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000279	0.00136	CcSEcCtD
Levomilnacipran—Eye disorder—Methotrexate—multiple sclerosis	0.000276	0.00135	CcSEcCtD
Levomilnacipran—Syncope—Prednisone—multiple sclerosis	0.000276	0.00135	CcSEcCtD
Levomilnacipran—Anorexia—Betamethasone—multiple sclerosis	0.000275	0.00134	CcSEcCtD
Levomilnacipran—Anorexia—Dexamethasone—multiple sclerosis	0.000275	0.00134	CcSEcCtD
Levomilnacipran—Urticaria—Prednisolone—multiple sclerosis	0.000275	0.00134	CcSEcCtD
Levomilnacipran—Cardiac disorder—Methotrexate—multiple sclerosis	0.000274	0.00134	CcSEcCtD
Levomilnacipran—Fatigue—Triamcinolone—multiple sclerosis	0.000274	0.00134	CcSEcCtD
Levomilnacipran—Fatigue—Methylprednisolone—multiple sclerosis	0.000274	0.00133	CcSEcCtD
Levomilnacipran—SLC6A2—central nervous system—multiple sclerosis	0.000272	0.0227	CbGeAlD
Levomilnacipran—Loss of consciousness—Prednisone—multiple sclerosis	0.000271	0.00132	CcSEcCtD
Levomilnacipran—Hypotension—Betamethasone—multiple sclerosis	0.00027	0.00132	CcSEcCtD
Levomilnacipran—Hypotension—Dexamethasone—multiple sclerosis	0.00027	0.00132	CcSEcCtD
Levomilnacipran—Angiopathy—Methotrexate—multiple sclerosis	0.000268	0.00131	CcSEcCtD
Levomilnacipran—Vomiting—Mitoxantrone—multiple sclerosis	0.000268	0.00131	CcSEcCtD
Levomilnacipran—Convulsion—Prednisone—multiple sclerosis	0.000267	0.0013	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000267	0.0013	CcSEcCtD
Levomilnacipran—Hypertension—Prednisone—multiple sclerosis	0.000266	0.0013	CcSEcCtD
Levomilnacipran—Rash—Mitoxantrone—multiple sclerosis	0.000266	0.0013	CcSEcCtD
Levomilnacipran—Dermatitis—Mitoxantrone—multiple sclerosis	0.000266	0.0013	CcSEcCtD
Levomilnacipran—Chills—Methotrexate—multiple sclerosis	0.000265	0.00129	CcSEcCtD
Levomilnacipran—SLC6A2—Monoamine Transport—IL1B—multiple sclerosis	0.000265	0.00581	CbGpPWpGaD
Levomilnacipran—Headache—Mitoxantrone—multiple sclerosis	0.000264	0.00129	CcSEcCtD
Levomilnacipran—Anxiety—Prednisone—multiple sclerosis	0.000261	0.00127	CcSEcCtD
Levomilnacipran—Insomnia—Betamethasone—multiple sclerosis	0.000261	0.00127	CcSEcCtD
Levomilnacipran—Insomnia—Dexamethasone—multiple sclerosis	0.000261	0.00127	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.00026	0.00127	CcSEcCtD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00026	0.00571	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00026	0.00571	CbGpPWpGaD
Levomilnacipran—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.00026	0.00127	CcSEcCtD
Levomilnacipran—Paraesthesia—Dexamethasone—multiple sclerosis	0.000259	0.00126	CcSEcCtD
Levomilnacipran—Paraesthesia—Betamethasone—multiple sclerosis	0.000259	0.00126	CcSEcCtD
Levomilnacipran—Mental disorder—Methotrexate—multiple sclerosis	0.000259	0.00126	CcSEcCtD
Levomilnacipran—Malnutrition—Methotrexate—multiple sclerosis	0.000257	0.00126	CcSEcCtD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000257	0.00563	CbGpPWpGaD
Levomilnacipran—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000257	0.00563	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Prednisolone—multiple sclerosis	0.000255	0.00124	CcSEcCtD
Levomilnacipran—Dyspepsia—Betamethasone—multiple sclerosis	0.000254	0.00124	CcSEcCtD
Levomilnacipran—Dyspepsia—Dexamethasone—multiple sclerosis	0.000254	0.00124	CcSEcCtD
Levomilnacipran—Urticaria—Triamcinolone—multiple sclerosis	0.000253	0.00123	CcSEcCtD
Levomilnacipran—Urticaria—Methylprednisolone—multiple sclerosis	0.000252	0.00123	CcSEcCtD
Levomilnacipran—Dysgeusia—Methotrexate—multiple sclerosis	0.000252	0.00123	CcSEcCtD
Levomilnacipran—Body temperature increased—Triamcinolone—multiple sclerosis	0.000251	0.00123	CcSEcCtD
Levomilnacipran—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000251	0.00122	CcSEcCtD
Levomilnacipran—Decreased appetite—Betamethasone—multiple sclerosis	0.000251	0.00122	CcSEcCtD
Levomilnacipran—Decreased appetite—Dexamethasone—multiple sclerosis	0.000251	0.00122	CcSEcCtD
Levomilnacipran—Nausea—Mitoxantrone—multiple sclerosis	0.00025	0.00122	CcSEcCtD
Levomilnacipran—Infection—Prednisone—multiple sclerosis	0.00025	0.00122	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000249	0.00122	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000249	0.00122	CcSEcCtD
Levomilnacipran—Fatigue—Dexamethasone—multiple sclerosis	0.000249	0.00121	CcSEcCtD
Levomilnacipran—Fatigue—Betamethasone—multiple sclerosis	0.000249	0.00121	CcSEcCtD
Levomilnacipran—Shock—Prednisone—multiple sclerosis	0.000247	0.00121	CcSEcCtD
Levomilnacipran—Nervous system disorder—Prednisone—multiple sclerosis	0.000247	0.0012	CcSEcCtD
Levomilnacipran—Tachycardia—Prednisone—multiple sclerosis	0.000245	0.0012	CcSEcCtD
Levomilnacipran—SLC6A4—brain—multiple sclerosis	0.000245	0.0205	CbGeAlD
Levomilnacipran—Skin disorder—Prednisone—multiple sclerosis	0.000244	0.00119	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Prednisone—multiple sclerosis	0.000243	0.00119	CcSEcCtD
Levomilnacipran—Vision blurred—Methotrexate—multiple sclerosis	0.000243	0.00118	CcSEcCtD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000242	0.00531	CbGpPWpGaD
Levomilnacipran—Anorexia—Prednisone—multiple sclerosis	0.00024	0.00117	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000236	0.00115	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000236	0.00115	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	0.000235	0.00515	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	0.000235	0.00515	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000234	0.00114	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000234	0.00114	CcSEcCtD
Levomilnacipran—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000234	0.00512	CbGpPWpGaD
Levomilnacipran—Leukopenia—Methotrexate—multiple sclerosis	0.00023	0.00112	CcSEcCtD
Levomilnacipran—Urticaria—Betamethasone—multiple sclerosis	0.000229	0.00112	CcSEcCtD
Levomilnacipran—Urticaria—Dexamethasone—multiple sclerosis	0.000229	0.00112	CcSEcCtD
Levomilnacipran—Dizziness—Prednisolone—multiple sclerosis	0.000229	0.00112	CcSEcCtD
Levomilnacipran—Asthenia—Triamcinolone—multiple sclerosis	0.000228	0.00111	CcSEcCtD
Levomilnacipran—Body temperature increased—Dexamethasone—multiple sclerosis	0.000228	0.00111	CcSEcCtD
Levomilnacipran—Body temperature increased—Betamethasone—multiple sclerosis	0.000228	0.00111	CcSEcCtD
Levomilnacipran—Abdominal pain—Betamethasone—multiple sclerosis	0.000228	0.00111	CcSEcCtD
Levomilnacipran—Abdominal pain—Dexamethasone—multiple sclerosis	0.000228	0.00111	CcSEcCtD
Levomilnacipran—Asthenia—Methylprednisolone—multiple sclerosis	0.000228	0.00111	CcSEcCtD
Levomilnacipran—Insomnia—Prednisone—multiple sclerosis	0.000227	0.00111	CcSEcCtD
Levomilnacipran—Paraesthesia—Prednisone—multiple sclerosis	0.000226	0.0011	CcSEcCtD
Levomilnacipran—Pruritus—Triamcinolone—multiple sclerosis	0.000225	0.0011	CcSEcCtD
Levomilnacipran—Pruritus—Methylprednisolone—multiple sclerosis	0.000225	0.0011	CcSEcCtD
Levomilnacipran—SLC6A4—Monoamine Transport—TNF—multiple sclerosis	0.000224	0.0049	CbGpPWpGaD
Levomilnacipran—Convulsion—Methotrexate—multiple sclerosis	0.000223	0.00109	CcSEcCtD
Levomilnacipran—Dyspepsia—Prednisone—multiple sclerosis	0.000221	0.00108	CcSEcCtD
Levomilnacipran—Chest pain—Methotrexate—multiple sclerosis	0.000219	0.00107	CcSEcCtD
Levomilnacipran—Decreased appetite—Prednisone—multiple sclerosis	0.000219	0.00107	CcSEcCtD
Levomilnacipran—Rash—Prednisolone—multiple sclerosis	0.000218	0.00106	CcSEcCtD
Levomilnacipran—Dermatitis—Prednisolone—multiple sclerosis	0.000218	0.00106	CcSEcCtD
Levomilnacipran—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000218	0.00477	CbGpPWpGaD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000218	0.00106	CcSEcCtD
Levomilnacipran—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000217	0.00106	CcSEcCtD
Levomilnacipran—Fatigue—Prednisone—multiple sclerosis	0.000217	0.00106	CcSEcCtD
Levomilnacipran—Headache—Prednisolone—multiple sclerosis	0.000217	0.00106	CcSEcCtD
Levomilnacipran—SLC6A2—brain—multiple sclerosis	0.000216	0.018	CbGeAlD
Levomilnacipran—Constipation—Prednisone—multiple sclerosis	0.000215	0.00105	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.000214	0.00469	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000211	0.00463	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000211	0.00463	CbGpPWpGaD
Levomilnacipran—Dizziness—Triamcinolone—multiple sclerosis	0.00021	0.00103	CcSEcCtD
Levomilnacipran—Dizziness—Methylprednisolone—multiple sclerosis	0.00021	0.00102	CcSEcCtD
Levomilnacipran—CYP2C8—Biological oxidations—CYP24A1—multiple sclerosis	0.000209	0.00458	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—CYP27B1—multiple sclerosis	0.000209	0.00458	CbGpPWpGaD
Levomilnacipran—Infection—Methotrexate—multiple sclerosis	0.000209	0.00102	CcSEcCtD
Levomilnacipran—Asthenia—Betamethasone—multiple sclerosis	0.000207	0.00101	CcSEcCtD
Levomilnacipran—Asthenia—Dexamethasone—multiple sclerosis	0.000207	0.00101	CcSEcCtD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000206	0.00452	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000206	0.00452	CbGpPWpGaD
Levomilnacipran—Nervous system disorder—Methotrexate—multiple sclerosis	0.000206	0.001	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000206	0.001	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000206	0.001	CcSEcCtD
Levomilnacipran—Nausea—Prednisolone—multiple sclerosis	0.000205	0.001	CcSEcCtD
Levomilnacipran—ABCB1—retina—multiple sclerosis	0.000205	0.0171	CbGeAlD
Levomilnacipran—Pruritus—Dexamethasone—multiple sclerosis	0.000204	0.000996	CcSEcCtD
Levomilnacipran—Pruritus—Betamethasone—multiple sclerosis	0.000204	0.000996	CcSEcCtD
Levomilnacipran—Skin disorder—Methotrexate—multiple sclerosis	0.000204	0.000995	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—SRM—multiple sclerosis	0.000203	0.00445	CbGpPWpGaD
Levomilnacipran—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000203	0.00099	CcSEcCtD
Levomilnacipran—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000203	0.00445	CbGpPWpGaD
Levomilnacipran—Vomiting—Triamcinolone—multiple sclerosis	0.000202	0.000986	CcSEcCtD
Levomilnacipran—Vomiting—Methylprednisolone—multiple sclerosis	0.000202	0.000984	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	0.000202	0.00442	CbGpPWpGaD
Levomilnacipran—Rash—Triamcinolone—multiple sclerosis	0.000201	0.000978	CcSEcCtD
Levomilnacipran—Dermatitis—Triamcinolone—multiple sclerosis	0.0002	0.000977	CcSEcCtD
Levomilnacipran—Anorexia—Methotrexate—multiple sclerosis	0.0002	0.000977	CcSEcCtD
Levomilnacipran—Rash—Methylprednisolone—multiple sclerosis	0.0002	0.000976	CcSEcCtD
Levomilnacipran—Dermatitis—Methylprednisolone—multiple sclerosis	0.0002	0.000975	CcSEcCtD
Levomilnacipran—Urticaria—Prednisone—multiple sclerosis	0.0002	0.000974	CcSEcCtD
Levomilnacipran—Headache—Triamcinolone—multiple sclerosis	0.000199	0.000972	CcSEcCtD
Levomilnacipran—Headache—Methylprednisolone—multiple sclerosis	0.000199	0.00097	CcSEcCtD
Levomilnacipran—Body temperature increased—Prednisone—multiple sclerosis	0.000199	0.000969	CcSEcCtD
Levomilnacipran—Abdominal pain—Prednisone—multiple sclerosis	0.000199	0.000969	CcSEcCtD
Levomilnacipran—Diarrhoea—Dexamethasone—multiple sclerosis	0.000198	0.000963	CcSEcCtD
Levomilnacipran—Diarrhoea—Betamethasone—multiple sclerosis	0.000198	0.000963	CcSEcCtD
Levomilnacipran—Hypotension—Methotrexate—multiple sclerosis	0.000196	0.000957	CcSEcCtD
Levomilnacipran—SLC6A2—Monoamine Transport—TNF—multiple sclerosis	0.000192	0.00421	CbGpPWpGaD
Levomilnacipran—Dizziness—Betamethasone—multiple sclerosis	0.000191	0.000931	CcSEcCtD
Levomilnacipran—Dizziness—Dexamethasone—multiple sclerosis	0.000191	0.000931	CcSEcCtD
Levomilnacipran—Insomnia—Methotrexate—multiple sclerosis	0.00019	0.000927	CcSEcCtD
Levomilnacipran—Nausea—Triamcinolone—multiple sclerosis	0.000189	0.000922	CcSEcCtD
Levomilnacipran—Paraesthesia—Methotrexate—multiple sclerosis	0.000189	0.00092	CcSEcCtD
Levomilnacipran—Nausea—Methylprednisolone—multiple sclerosis	0.000189	0.00092	CcSEcCtD
Levomilnacipran—CYP2J2—Biological oxidations—POMC—multiple sclerosis	0.000188	0.00413	CbGpPWpGaD
Levomilnacipran—Dyspnoea—Methotrexate—multiple sclerosis	0.000187	0.000913	CcSEcCtD
Levomilnacipran—Somnolence—Methotrexate—multiple sclerosis	0.000187	0.000911	CcSEcCtD
Levomilnacipran—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000187	0.00409	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.000186	0.00409	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.000186	0.00409	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Prednisone—multiple sclerosis	0.000185	0.000903	CcSEcCtD
Levomilnacipran—Dyspepsia—Methotrexate—multiple sclerosis	0.000185	0.000902	CcSEcCtD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000184	0.00403	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000184	0.00403	CbGpPWpGaD
Levomilnacipran—Vomiting—Betamethasone—multiple sclerosis	0.000184	0.000895	CcSEcCtD
Levomilnacipran—Vomiting—Dexamethasone—multiple sclerosis	0.000184	0.000895	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	0.000183	0.00401	CbGpPWpGaD
Levomilnacipran—Decreased appetite—Methotrexate—multiple sclerosis	0.000183	0.000891	CcSEcCtD
Levomilnacipran—Rash—Dexamethasone—multiple sclerosis	0.000182	0.000888	CcSEcCtD
Levomilnacipran—Rash—Betamethasone—multiple sclerosis	0.000182	0.000888	CcSEcCtD
Levomilnacipran—Dermatitis—Betamethasone—multiple sclerosis	0.000182	0.000887	CcSEcCtD
Levomilnacipran—Dermatitis—Dexamethasone—multiple sclerosis	0.000182	0.000887	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000181	0.000885	CcSEcCtD
Levomilnacipran—Fatigue—Methotrexate—multiple sclerosis	0.000181	0.000883	CcSEcCtD
Levomilnacipran—Headache—Dexamethasone—multiple sclerosis	0.000181	0.000882	CcSEcCtD
Levomilnacipran—Headache—Betamethasone—multiple sclerosis	0.000181	0.000882	CcSEcCtD
Levomilnacipran—Asthenia—Prednisone—multiple sclerosis	0.00018	0.00088	CcSEcCtD
Levomilnacipran—Pruritus—Prednisone—multiple sclerosis	0.000178	0.000867	CcSEcCtD
Levomilnacipran—CYP2C8—brain—multiple sclerosis	0.000177	0.0148	CbGeAlD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000173	0.0038	CbGpPWpGaD
Levomilnacipran—Diarrhoea—Prednisone—multiple sclerosis	0.000172	0.000839	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000172	0.000838	CcSEcCtD
Levomilnacipran—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.000172	0.00376	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.000172	0.00376	CbGpPWpGaD
Levomilnacipran—Nausea—Betamethasone—multiple sclerosis	0.000171	0.000836	CcSEcCtD
Levomilnacipran—Nausea—Dexamethasone—multiple sclerosis	0.000171	0.000836	CcSEcCtD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000169	0.00371	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000169	0.00371	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000169	0.00371	CbGpPWpGaD
Levomilnacipran—Urticaria—Methotrexate—multiple sclerosis	0.000167	0.000814	CcSEcCtD
Levomilnacipran—Dizziness—Prednisone—multiple sclerosis	0.000166	0.000811	CcSEcCtD
Levomilnacipran—Body temperature increased—Methotrexate—multiple sclerosis	0.000166	0.00081	CcSEcCtD
Levomilnacipran—Abdominal pain—Methotrexate—multiple sclerosis	0.000166	0.00081	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.000165	0.00362	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000162	0.00356	CbGpPWpGaD
Levomilnacipran—Vomiting—Prednisone—multiple sclerosis	0.00016	0.000779	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000159	0.00348	CbGpPWpGaD
Levomilnacipran—Rash—Prednisone—multiple sclerosis	0.000158	0.000773	CcSEcCtD
Levomilnacipran—Dermatitis—Prednisone—multiple sclerosis	0.000158	0.000772	CcSEcCtD
Levomilnacipran—Headache—Prednisone—multiple sclerosis	0.000157	0.000768	CcSEcCtD
Levomilnacipran—CYP3A4—nervous system—multiple sclerosis	0.000157	0.0131	CbGeAlD
Levomilnacipran—Hypersensitivity—Methotrexate—multiple sclerosis	0.000155	0.000755	CcSEcCtD
Levomilnacipran—CYP2D6—nervous system—multiple sclerosis	0.000154	0.0129	CbGeAlD
Levomilnacipran—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000154	0.00338	CbGpPWpGaD
Levomilnacipran—CYP3A4—central nervous system—multiple sclerosis	0.000151	0.0126	CbGeAlD
Levomilnacipran—Asthenia—Methotrexate—multiple sclerosis	0.000151	0.000735	CcSEcCtD
Levomilnacipran—Nausea—Prednisone—multiple sclerosis	0.000149	0.000728	CcSEcCtD
Levomilnacipran—CYP2D6—central nervous system—multiple sclerosis	0.000149	0.0124	CbGeAlD
Levomilnacipran—Pruritus—Methotrexate—multiple sclerosis	0.000149	0.000725	CcSEcCtD
Levomilnacipran—ABCB1—medulla oblongata—multiple sclerosis	0.000148	0.0124	CbGeAlD
Levomilnacipran—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000148	0.00324	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000146	0.00321	CbGpPWpGaD
Levomilnacipran—CYP2D6—cerebellum—multiple sclerosis	0.000145	0.0121	CbGeAlD
Levomilnacipran—Diarrhoea—Methotrexate—multiple sclerosis	0.000144	0.000701	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—CYP24A1—multiple sclerosis	0.000143	0.00314	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CYP27B1—multiple sclerosis	0.000143	0.00314	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000141	0.00309	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.00014	0.00307	CbGpPWpGaD
Levomilnacipran—Dizziness—Methotrexate—multiple sclerosis	0.000139	0.000678	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000139	0.00304	CbGpPWpGaD
Levomilnacipran—ABCB1—midbrain—multiple sclerosis	0.000135	0.0113	CbGeAlD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000134	0.00294	CbGpPWpGaD
Levomilnacipran—Vomiting—Methotrexate—multiple sclerosis	0.000134	0.000651	CcSEcCtD
Levomilnacipran—Rash—Methotrexate—multiple sclerosis	0.000132	0.000646	CcSEcCtD
Levomilnacipran—Dermatitis—Methotrexate—multiple sclerosis	0.000132	0.000645	CcSEcCtD
Levomilnacipran—ABCB1—spinal cord—multiple sclerosis	0.000132	0.011	CbGeAlD
Levomilnacipran—Headache—Methotrexate—multiple sclerosis	0.000132	0.000642	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—GPC5—multiple sclerosis	0.000131	0.00287	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000127	0.00278	CbGpPWpGaD
Levomilnacipran—Nausea—Methotrexate—multiple sclerosis	0.000125	0.000609	CcSEcCtD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000123	0.0027	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.000122	0.00268	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—FAS—multiple sclerosis	0.000121	0.00265	CbGpPWpGaD
Levomilnacipran—CYP2D6—brain—multiple sclerosis	0.000118	0.00986	CbGeAlD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	0.000114	0.0025	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000112	0.00246	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000112	0.00246	CbGpPWpGaD
Levomilnacipran—ABCB1—nervous system—multiple sclerosis	0.000111	0.00928	CbGeAlD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000111	0.00242	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000111	0.00242	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CD86—multiple sclerosis	0.00011	0.00241	CbGpPWpGaD
Levomilnacipran—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000109	0.00239	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—RRM1—multiple sclerosis	0.000108	0.00238	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL10—multiple sclerosis	0.000108	0.00237	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	0.000108	0.00237	CbGpPWpGaD
Levomilnacipran—ABCB1—central nervous system—multiple sclerosis	0.000107	0.00894	CbGeAlD
Levomilnacipran—ABCB1—Allograft Rejection—IL4—multiple sclerosis	0.000105	0.0023	CbGpPWpGaD
Levomilnacipran—ABCB1—cerebellum—multiple sclerosis	0.000105	0.00874	CbGeAlD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	0.000103	0.00225	CbGpPWpGaD
Levomilnacipran—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.74e-05	0.00213	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	9.72e-05	0.00213	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—FAS—multiple sclerosis	9.68e-05	0.00212	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	9.62e-05	0.00211	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	9.51e-05	0.00208	CbGpPWpGaD
Levomilnacipran—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.96e-05	0.00196	CbGpPWpGaD
Levomilnacipran—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.85e-05	0.00194	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	8.69e-05	0.0019	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	8.68e-05	0.0019	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	8.6e-05	0.00188	CbGpPWpGaD
Levomilnacipran—ABCB1—brain—multiple sclerosis	8.49e-05	0.0071	CbGeAlD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.41e-05	0.00184	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—CD80—multiple sclerosis	8.03e-05	0.00176	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	8.02e-05	0.00176	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	8.02e-05	0.00176	CbGpPWpGaD
Levomilnacipran—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.9e-05	0.00173	CbGpPWpGaD
Levomilnacipran—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.26e-05	0.00159	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.23e-05	0.00158	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	7.16e-05	0.00157	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	7.16e-05	0.00157	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	7.15e-05	0.00157	CbGpPWpGaD
Levomilnacipran—SLC6A4—NRF2 pathway—TGFB1—multiple sclerosis	7.11e-05	0.00156	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	6.95e-05	0.00152	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.59e-05	0.00144	CbGpPWpGaD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	6.46e-05	0.00142	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	6.35e-05	0.00139	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—TNF—multiple sclerosis	6.29e-05	0.00138	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—BCHE—multiple sclerosis	6.23e-05	0.00137	CbGpPWpGaD
Levomilnacipran—SLC6A2—NRF2 pathway—TGFB1—multiple sclerosis	6.11e-05	0.00134	CbGpPWpGaD
Levomilnacipran—SLC6A2—SLC-mediated transmembrane transport—ALB—multiple sclerosis	6.09e-05	0.00133	CbGpPWpGaD
Levomilnacipran—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.86e-05	0.00128	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	5.66e-05	0.00124	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL2—multiple sclerosis	5.64e-05	0.00124	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	5.58e-05	0.00122	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	5.42e-05	0.00119	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—IL6—multiple sclerosis	5.08e-05	0.00111	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SRM—multiple sclerosis	5.07e-05	0.00111	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	4.78e-05	0.00105	CbGpPWpGaD
Levomilnacipran—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.75e-05	0.00104	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—POMC—multiple sclerosis	4.7e-05	0.00103	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SRM—multiple sclerosis	4.53e-05	0.000992	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SRM—multiple sclerosis	4.42e-05	0.000968	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	4.4e-05	0.000964	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	4.28e-05	0.000938	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—POMC—multiple sclerosis	4.19e-05	0.000919	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SRM—multiple sclerosis	4.16e-05	0.000912	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—IL6—multiple sclerosis	4.15e-05	0.000909	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TNF—multiple sclerosis	4.11e-05	0.0009	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—POMC—multiple sclerosis	3.86e-05	0.000845	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.79e-05	0.00083	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—APOE—multiple sclerosis	3.75e-05	0.000821	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	3.57e-05	0.000783	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	3.57e-05	0.000783	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.49e-05	0.000765	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GPC5—multiple sclerosis	3.27e-05	0.000716	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—POMC—multiple sclerosis	3.22e-05	0.000705	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	3.19e-05	0.000699	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	3.19e-05	0.000699	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.12e-05	0.000683	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP27B1—multiple sclerosis	3.11e-05	0.000682	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP24A1—multiple sclerosis	3.11e-05	0.000682	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.1e-05	0.000678	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ALB—multiple sclerosis	2.94e-05	0.000643	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.93e-05	0.000643	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.93e-05	0.000643	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.92e-05	0.000639	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GPC5—multiple sclerosis	2.85e-05	0.000624	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SRM—multiple sclerosis	2.72e-05	0.000596	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—RRM1—multiple sclerosis	2.71e-05	0.000593	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GPC5—multiple sclerosis	2.68e-05	0.000588	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.52e-05	0.000553	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—RRM1—multiple sclerosis	2.42e-05	0.00053	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—RRM1—multiple sclerosis	2.36e-05	0.000517	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—RRM1—multiple sclerosis	2.22e-05	0.000487	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.18e-05	0.000477	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.17e-05	0.000476	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.13e-05	0.000467	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.1e-05	0.00046	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.03e-05	0.000444	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.92e-05	0.00042	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.92e-05	0.00042	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.88e-05	0.000411	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.8e-05	0.000395	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.75e-05	0.000384	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.65e-05	0.000361	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.61e-05	0.000353	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.56e-05	0.000341	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.47e-05	0.000322	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.45e-05	0.000318	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.39e-05	0.000304	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.36e-05	0.000299	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—BCHE—multiple sclerosis	1.35e-05	0.000297	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.28e-05	0.00028	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—APOE—multiple sclerosis	9.36e-06	0.000205	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—APOE—multiple sclerosis	8.35e-06	0.000183	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—BCHE—multiple sclerosis	8.35e-06	0.000183	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—APOE—multiple sclerosis	8.15e-06	0.000179	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—POMC—multiple sclerosis	8.04e-06	0.000176	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—APOE—multiple sclerosis	7.68e-06	0.000168	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALB—multiple sclerosis	7.33e-06	0.000161	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—POMC—multiple sclerosis	7.17e-06	0.000157	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—POMC—multiple sclerosis	7e-06	0.000153	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—POMC—multiple sclerosis	6.6e-06	0.000145	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALB—multiple sclerosis	6.54e-06	0.000143	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALB—multiple sclerosis	6.38e-06	0.00014	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALB—multiple sclerosis	6.02e-06	0.000132	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—APOE—multiple sclerosis	5.02e-06	0.00011	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—POMC—multiple sclerosis	4.31e-06	9.45e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALB—multiple sclerosis	3.93e-06	8.62e-05	CbGpPWpGaD
